유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

novo nordisk a/s - liraglutiid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - victoza on näidustatud ravi täiskasvanutel, noorukitel ja lastel vanuses 10 aastat ja vanemad, kellel ei ole piisavalt kontrollitud tüüp 2 diabeet lisandina toitumise ja exerciseas monotherapy kui metformiin on ebasobivaks, kuna talumatus või contraindicationsin lisaks teiste ravimitega ravi diabeet. uuringu tulemused seoses kombinatsioonid, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud.

에스토니아 - 에스토니아어 - Ravimiamet

sandoz pharmaceuticals d.d. - nebivolool - tablett - 5mg 50tk; 5mg 30tk; 5mg 500tk; 5mg 56tk; 5mg 90tk; 5mg 10tk; 5mg 100tk; 5mg 14tk; 5mg 20tk

에스토니아 - 에스토니아어 - Ravimiamet

berlin-chemie ag - sulfametoksasool+trimetoprim - tablett - 800mg+160mg 10tk

에스토니아 - 에스토니아어 - Ravimiamet

bayer pharma ag - noretisteroon+östradiool - õhukese polümeerikattega tablett - 1mg+2mg 84tk

에스토니아 - 에스토니아어 - Ravimiamet

bayer ag - dienogest+östradioolvaleraat - õhukese polümeerikattega tablett - 0+3mg/0+1mg/0+0/2mg+2mg/3mg+2mg 6tk / 6tk / 6tk / 15tk / 51tk; 0+3mg/0+1mg/0+0/2mg+2mg/3mg+2mg 12tk / 12tk / 12tk / 35tk / 102tk

에스토니아 - 에스토니아어 - Ravimiamet

krka d.d. novo mesto - amiodaroon - tablett - 200mg 60tk

에스토니아 - 에스토니아어 - Ravimiamet

karolinska university hospital - fludeoksüglükoos (18f) - süstelahus - 1tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leukeemia, müeloidne, äge - antineoplastilised ained - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.